Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412756 | 0.89 | ALDH1A1 (0.40) | ALDH1A1CYP2C9CYP2C19KMT2ALRRK2 | |
| SCHEMBL10189728 | 0.85 | SMPD3 (0.41) | ALDH1A1KMT2AKDM4ELMNAHSD17B10 | |
| SCHEMBL10189703 | 0.83 | SMPD3 (0.41) | ALDH1A1KMT2AKDM4ELMNAHSD17B10 | |
| SCHEMBL10189699 | 0.82 | ALDH1A1 (0.35) | ALDH1A1KDM4EPDE4B | |
| SCHEMBL10189702 | 0.81 | CHEK1 (0.38) | ALDH1A1KMT2ASMN1; SMN2TDP1KDM4E | |
| SCHEMBL410895 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP2C9CYP2C19KMT2ALRRK2 | |
| SCHEMBL10189754 | 0.81 | SMPD3 (0.34) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10189705 | 0.80 | S1PR1 (0.38) | SMN1; SMN2 | |
| SCHEMBL10189708 | 0.80 | S1PR1 (0.37) | ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL10189723 | 0.79 | FYN (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885CYP2C9 4488/4885CYP2C19 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.